Key result
Linagliptin provides comparable glycemic efficacy and DPP-4 inhibition across Japanese, Asian, and white patients.
Why the study?
The efficacy and safety of drugs can vary between different races or ethnic populations due to differences in dose-exposure relationships, pharmacodynamics, or clinical outcomes.
Does linagliptin 5 mg once-daily monotherapy have comparable pharmacodynamics, efficacy, and safety across Japanese, Asian, and white patients with type 2 diabetes?
RCT (n=741)
Does linagliptin 5 mg once-daily monotherapy have comparable pharmacodynamics, efficacy, and safety across Japanese, Asian, and white patients with type 2 diabetes?
Linagliptin 5 mg once daily provides consistent pharmacodynamic and clinical efficacy across Japanese, Asian, and white patients with type 2 diabetes.
Answers are grounded in this paper and cite their sources.
Supports standard linagliptin dosing without ethnic adjustment; confirms consistent efficacy across Japanese, Asian, and white T2D patients.
AIMS/INTRODUCTION: The efficacy and safety of drugs can vary between different races or ethnic populations because of differences in the relationship of dose to exposure, pharmacodynamic response or clinical efficacy and safety. In the present post-hoc analysis, we assessed the influence of race on the pharmacokinetics, pharmacodynamics, efficacy and safety of monotherapy with the dipeptidyl peptidase-4 inhibitor, linagliptin, in patients with type 2 diabetes enrolled in two comparable, previously reported randomized phase III trials. MATERIALS AND METHODS: Study 1 (with a 12-week placebo-controlled phase) recruited Japanese patients only (linagliptin, n = 159; placebo, n = 80); study 2 (24-week trial) enrolled Asian (non-Japanese; linagliptin, n = 156; placebo, n = 76) and white patients (linagliptin, n = 180; placebo, n = 90). RESULTS: Linagliptin trough concentrations were equivalent across study and race groups, and were higher than half-maximal inhibitory concentration, resulting in dipeptidyl peptidase-4 inhibition >80% at trough. Linagliptin inhibited plasma dipeptidyl peptidase-4 activity to a similar degree in study 1 and study 2. Linagliptin reduced fasting plasma glucose concentrations by a similar magnitude across groups, leading to clinically relevant reductions in glycated hemoglobin in all groups. Glycated hemoglobin levels decreased to a slightly greater extent in study 1 (Japanese) and in Asian (non-Japanese) patients from study 2. Linagliptin had a favorable safety profile in each race group. CONCLUSIONS: Trough exposure, pharmacodynamic response, and efficacy and safety of linagliptin monotherapy were comparable among Japanese, Asian (non-Japanese) and white patients, confirming that the recommended 5-mg once-daily dose of linagliptin is appropriate for use among different race groups.
No takes yet. Share an insight, caveat, or question.
Sarashina et al. (2016) conducted an RCT in type 2 diabetes (n=741). linagliptin vs. placebo was evaluated on pharmacokinetics, pharmacodynamics, efficacy and safety. Linagliptin once-daily provided comparable trough exposure, dipeptidyl peptidase-4 inhibition, and glycemic efficacy across Japanese, Asian, and white patients with type 2 diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: